ZYUS Life Sciences’ (ZYU) “Buy” Rating Reiterated at Roth Capital
Roth Capital reiterated their buy rating on shares of ZYUS Life Sciences (CVE:ZYU – Free Report) in a report published on Thursday, PriceTargets.com reports. Separately, Stifel Canada reissued a speculative buy rating on shares of ZYUS Life Sciences in a research note on Friday, January 26th. Check Out Our Latest Research Report on ZYUS Life […]
More Stories
New Listings Tick Up 3 Percent as Mortgage Rates Continue to Slide
By Rob Sabo New home listings are on the rise across the United States, potentially spurred by hopes of falling...
US, EU Sign Preliminary Partnership Deal on Critical Minerals
By Owen Evans The United States and the European Union signed a memorandum of understanding on April 24 for a...
DOJ Approves Firing Squads for Federal Death Penalty Cases
By Michael Clements The Department of Justice (DOJ) has authorized firing squads, electrocution, and gassing as a means of execution...
Trump Extends Jones Act Waiver for 90 Days to Ease Energy Crunch
By Tom Ozimek President Donald Trump has extended a waiver of the century-old Jones Act for 90 days, allowing foreign-flagged...
Canada Rescinds Digital Services Tax After Trump Halts Trade Talks
By Omid Ghoreishi The Canadian government is rescinding its digital services tax to avoid stalling trade talks with the United...
Trump Floats Taxpayer-Funded Takeover of Spirit Airlines, Selling for Profit
By Chris Summers President Donald Trump said on April 23 that a taxpayer-funded takeover of Spirit Airlines could be an...